




# The next generation

*One of the earliest examples of mentoring occurred in ancient Greece.*

HOMER TELLS US IN THE ODYSSEY that Odysseus, King of Ithaca, asked his friend Mentor to keep an eye on his son Telemachus while he was away fighting the Trojan War. A more recent example is the 19th century British scientist Michael Faraday, who was apprenticed to a bookbinder, read a book about science and decided that would be his career. He then wrote to Sir Humphrey Davy, a lecturer in chemistry at the Royal Institution, to ask for a job and was hired as a laboratory assistant. He became an analytical chemist, best known for his work in electricity.

Alison Kydd, one of Dr. David Hart's students at the University of Calgary, is completing the first year of her MD/PhD studies as part of the MD/PhD program. She met Dr. Hart as a grade 11 student, when she participated in a High School Enrichment Program. The program identifies talented young people and places them in laboratories where they can see how research is conducted. She was fortunate to meet Dr. Hart who became her mentor. Subsequent research



Dr. David Hart and Alison Kydd

Dot Brown

## Contents

1. The next generation
3. Diverse experiences
4. One woman's battle
5. Leading the way
6. CAN 2003 Annual Scientific Conference
8. CAN Annual General Meeting

as a summer student during university reinforced Alison's interest in a research career. Dr. Hart says "the High School and Summer Programs are invaluable – they expose students to areas of research they are not familiar with and then they can get excited about something or find out it's not the place for them."

A professor in the Departments of Surgery (Orthopaedics), Medicine (Rheumatology), and Microbiology & Infectious Diseases, Dr. Hart does research on the molecular and cell biology of connective tissue healing and repair. He is a member of the Canadian

Arthritis Network's management committee and bioengineering for joint reconstruction theme.

Dr. Hart grew up in Michigan, obtained a PhD in biochemistry and did post-doctoral work in immunology, which led to an interest in inflammation, and subsequently, wound healing. This has led to his current research directions in the areas of ligament and tendon healing and repair, osteoarthritis with a focus on the meniscus, the interface between biology and biomechanics (mechanobiology), and the role of sex/gender influences on

continued on page 2

---

## The next generation

continued from page 1

these processes. While most of his research is focused on experimental models, he collaborates extensively with clinician-scientists, kinesiologists, and engineers to move the research findings forward to potential clinical applications.

While on the faculty at Southwestern Medical School in Texas, he heard about the University of Calgary from a colleague who had been interviewed for a job there. Intrigued by the research environment that offered multi-disciplinary research groups, he applied for a position, was hired, and moved to



“Students have to show motivation and develop some passion for doing research. I use that as a benchmark for investing time and effort to help them.”

Dr. David Hart

Calgary where he met Drs. Marv Fritzier and Cy Frank. Along with other colleagues, they developed the initial concept of the Joint Injury and Arthritis Research Group. The Group raised more than \$5 million from the community to develop what has become the McCaig Centre for Joint Injury and Arthritis Research. “It has been an exciting journey over the past 18 years,” Dr. Hart says and he is looking forward to the expansion of the McCaig Centre in the next few years when a new building at the University of Calgary is completed. This building, along with new arthritis and joint health related initiatives in Engineering, Kinesiology and Science, will create an exciting research environment and the opportunity to interact in new areas and directions, including the

translation of research into the clinical realm. According to Dr. Hart, “This is the fun part of doing research, and I have found many people don’t actually end up doing what they were initially trained to do. From my perspective, doing research has to be dynamic and in constant evolution in order to keep moving forward, and one way to do this is to work with others interested in similar problems.” He believes that this type of environment is also critical for the development of the next generation of investigators who will in many cases be working in transdisciplinary research teams.

When Dr. Hart met Alison Kydd, he saw a student who was self-motivated

and who had a passion for science. He sees the role of a mentor as one of “helping students achieve their own potential. Students have to show motivation and develop some passion for doing research. I use that as the benchmark for investing time and effort to help them.” In looking back on his own career, Dr. Hart had such a mentor in high school and later at university who helped him develop his interest in a career in science. He did research in the summers with his mentor in a biochemistry lab and realized during his third year at university that he wanted a career in scientific research.

Kydd had a variety of interests in high school including drama, sports and medical research. Her high school chemistry teacher submitted her name for the High

School Enrichment Program where she met and worked with Drs. Hart and Frank. After graduation she enrolled in the Science faculty at the University of Calgary, working as a biochemistry undergraduate with Dr. Hart on a few different projects including ligament healing, autoimmune inflammatory disease, and investigating the effects of hormones on tissue healing. She has continued the latter research for her PhD studies.

While she was an undergraduate, Kydd explored the idea of an international learning experience. She was inspired to do this after listening to a lecture by a visiting Swedish doctor. Dr. Hart was able to introduce her to Dr. Dick Heinegård at the University of Lund in Sweden, an internationally known protein biochemist who does research on cartilage and other connective tissues. She spent eight months in Sweden, working on her Honours research project in his laboratory and studying immunology.

Dr. Hart explained the University of Calgary’s MD/PhD program to her on her return and they agreed it was a good fit for her. She did two years of research for her PhD on the effect of glucocorticoids, other steroids, and hormones on healing in injured joints and joints affected by osteoarthritis before starting the Medical School side of her training. She has also been visiting orthopedic and rheumatology clinics as part of her medical training and sees patients receiving injections of the steroids she has been studying. Thus, she is able to integrate her research perspective with her clinical training.

Kydd’s plans are to obtain both degrees in 2007, complete her residency and combine the practice of medicine with research. She says “there is good support now for clinician scientists. It provides an opportunity to do research and also teach that you don’t always have when you are focused only on clinical work.”

She says she “lucked out when I met these amazing people at the University of Calgary.” In addition to helping Alison develop her research skills, Dr. Hart has also assisted her in developing a presentation style and helped her learn how to write papers and manuscripts. Alison says

continued on page 8

---

# Sometimes diverse experiences converge on the perfect job

*Parallel interests in health care and science have brought Linda Bennett to a position where she is having a positive impact on the research landscape in Canada.*

BENNETT IS THE EXECUTIVE Director of the Canadian Rheumatology Research Consortium (CRRRC), an alliance of academic and community rheumatologists who have expertise in the conduct of all phases of pharmaceutical industry-sponsored clinical trials. Their mission, to increase the volume and scope of trials performed in Canada, will ensure that Canadians with arthritis will have earlier access to novel and effective treatments.

Bennett's role is similar to that of a project manager. She identifies the elements that are critical to the success of the Consortium, then brings together the necessary resources, and drives the process while monitoring the progress. Accountable to the CRRRC Board of Directors, her contribution impacts everything from organizational strategy to operational details. "Every facet of building the organization is important to its success," she says. The job has "all the thrive or die elements of a start-up."

As a self-directed learner, Bennett delved into things that interested her. Science and math in high school led her to nursing, biology and physics at university. The divergence in Bennett's educational interests was a prelude to the work experience that would follow. "In the beginning, I nurtured two career paths simultaneously. Upon reflection, I believe I did this because I had strong mentors in each area of interest. Today, I count those three women among my closest friends and they still play a meaningful role in my life."

For several years during university, Bennett worked at a health clinic that provided education and counseling, primarily to women. Dr. Ruth Kurtz, a clinical psychologist and Laura Fischer, a public health nurse, inspired her. "It was a privilege to work with such intelligent,

insightful and highly skilled women so early in my career. They not only stimulated my desire to learn and enhance my skills, but in so many ways their encouragement and support helped shape the person that I am now." It was at this clinic that Bennett coordinated her first clinical trial and met Dr. Alice Marshall, Associate Director of Clinical

**CAN nurtured and supported the development of the consortium. The strategic alliance between CAN and CRRRC will create a research environment that enhances Canada's competitiveness in the global marketplace.**

---

Affairs at Wyeth Pharmaceuticals.

After graduating from the University of Toronto with a degree in science, Bennett worked for Wyeth as a clinical research associate. "In the five years that I worked with Alice Marshall, I learned a tremendous amount from her. With a PhD (pharmacology), MBA, years of clinical research experience, and a willingness to share what she knows, it is difficult to find a better teacher."

Concurrent part-time work on the Ontario Ministry of Health AIDS hotline brought Bennett into the public health arena and she moved into a full-time opening with an AIDS prevention program. Although she found working directly with the program's clients meaningful and rewarding, Bennett missed clinical research, particularly "the rigor of

the science and process involved in drug development. It is fascinating to see data for the first time and to uncover the true experience with a product in the clinical research setting." She subsequently joined another pharmaceutical company and established a global compassionate (special) access program for an investigational therapy. Health Canada's Therapeutic Products Directorate's Special Access Program enables patients with serious or life-threatening conditions to obtain non-marketed treatments through their physicians.

The experience with project management and clinical trials was invaluable when Bennett worked at a biotechnology company as the associate director of clinical development. This company with its first product in Phase II of clinical development had limited infrastructure and resources. Each member of the development team brought a unique skill set and experience to the project and together, they accomplished a great deal at a rapid pace. Her industry experience provided ample opportunity to learn

from her peers. Bennett says, "I have had the good fortune to work with bright, strategic, engaging, dedicated and hard working colleagues during my career. Working with people of this caliber has contributed significantly to my own development."

The Canadian Arthritis Network (CAN) recruited Bennett to manage the clinical trials group. Dr. Ed Keystone, a CAN member, developed the idea of establishing a consortium to do clinical trials in rheumatology. Other rheumatologists confirmed their interest in participating. Bennett supported the group, helping them to stay focused and on track to meet their goals. She did research, networked with other consortia, met with pharmaceutical com-

continued on page 4

panies and spoke with consumers. Within a year, the CRRC was incorporated federally as a non-profit organization and shortly thereafter, held its first Annual General Meeting of the members. Dr. Keystone describes Bennett as “the driving force behind the development of the CRRC. Her outstanding abilities, work ethic, political savvy and vision have moved this from a concept to reality.”

Bennett is now setting up the infrastructure that will help sponsors with site selection and reduce study start-up time. A national Web-enabled clinical trials patient registry to expedite recruitment is in the works.

CAN nurtured and supported the development of the consortium. The strategic alliance between CAN and CRRC will create a research environment that enhances Canada’s competitiveness in the global marketplace. Together they offer the pharmaceutical and biotechnology industries a highly desirable bench-to-bedside range of arthritis-related expertise and services. Bennett says, “The partnership is unprecedented and creates an opportunity for researchers, trialists, study coordinators, consumers and sponsors to work together to advance arthritis research. Canada is positioned



Dr. Ed Keystone

to be a global leader in the discovery and development of arthritis treatments.”

Bennett is enjoying her role in the CRRC. “This is the perfect opportunity to utilize the full breadth of the skills and knowledge that I have gained from my previous experiences. From clinical research to project management to health care advocacy – all of it is relevant in this position”, she says. “It is an exciting opportunity do something new that will enhance drug development in Canada.” ■

# One woman’s battle with rheumatoid arthritis

*June Dixon is a warrior and her battlefield is her own body. The enemy is rheumatoid arthritis (RA). Who is winning?*

RIGHT NOW, DIXON APPEARS to be ahead, with the help of medical treatment and new drugs. At a presentation held in Toronto by Rx&D (the association of Canada’s research-based pharmaceutical companies), she shared her story about the ravages of RA and her effort to remain healthy and active.

RA struck Dixon in the prime of life. She received a BA from the University of Toronto and enjoyed a 30-year career as a manager with a pharmaceutical company. She was married, with grown children. At the time RA struck, Dixon and her husband were both happy in their careers and enjoyed good health. With no warning Dixon suffered an attack of severe pain in her arm and nausea while Christmas shopping in a mall.

Describing what followed, Dixon said, “I experienced shock, disbelief and denial. I learned to live with pain 24/7. My body attacked healthy tissue and ugly nodules appeared. My fingers were deformed and I could scarcely hold a pen. Touching a keyboard was agony. The disease was unpredictable and agonizing.”

Dixon refused to give in to the disease and continued to work between flare-ups. She tried all the standard treatments and had ankle fusion surgery, eventually giving up working because it interfered with her treatments. Feeling defeated by the disease Dixon decided to become proactive. She found information on The Arthritis Society’s Web page and joined Patient Partners® in Arthritis, implemented by Dr. Mary Bell, a rheumatologist at Sunnybrook and Women’s College Health Sciences Centre. The program,

managed by Terri Lupton, National Coordinator, helps train health care professionals to conduct musculoskeletal examinations.

With her rheumatologist, Dixon began to investigate new drug therapies. She waited three months to obtain provincial government approval for Enbrel and

within three months of starting on the drug began to be mobile again. She recovered well enough to have reconstructive surgery on her feet last November. But the road to recovery was not smooth. She found out in late December that her

application for Enbrel for 2003 was not received by the government and it took three months before she was able to take the drug again. During the three months she waited, the progress she had made the previous year was lost. With less mobility, she fell down the stairs and sustained a stress fracture in her foot. Dixon’s experience with access to medication is not unusual in Canada where regulations vary by province and obtaining new or expensive drugs can be slow even if one is familiar with the process.

That experience has made Dixon an advocate for faster and simpler access to new medication. Is she winning the war on RA? We are betting on Dixon. She has won some significant battles. An articulate spokesperson for people with RA, she presents a compelling argument for the need for education about arthritis and for changes in government regulations.

For information on Patient Partners please contact Terri Lupton at 416-480-5792 or by e-mail at [terri.lupton@swchsc.on.ca](mailto:terri.lupton@swchsc.on.ca) ■



June Dixon and Chris Nelson, President and CEO, Canadian Arthritis Network

J.D. Kaplan

# Leading the way: basic science, bone cells, cartilage and arthritis

*“Push yourself to the limit, don’t settle for just getting by”,  
Dr. Jane Aubin tells her students and postdoctoral fellows.*

A PROFESSOR IN THE Department of Molecular and Medical Genetics at the University of Toronto, she is also cross appointed to the Department of Medical Biophysics, Faculty of Dentistry, Institute of Biomaterials and Biomedical Engineering and Institute of Medical Science, a member of the Collaborative PhD Program in Developmental Biology and co-coordinator of the Molecular Medicine theme in undergraduate medicine. Dr. Aubin listens to her own advice.

Dr. Aubin was the first woman to complete the program for a PhD in medical biophysics at the University of Toronto and is now a leading researcher on bone development. She uses models combining cellular, molecular and developmental biology to find out how stem cells become osteoblasts (bone-forming cells) and other types of cells. She also studies the effects of hormones, cytokines and growth factors on bone cell formation and activity.

When the Canadian Arthritis Network was formed, “Robin Poole and Tony Cruz were quite strong on the idea that excellent basic science is being done in Canada and it should be part of the arthritis research” says Dr. Aubin. She added, “It made me decide that we should devote some time to arthritis.” Dr. Aubin is now the scientific co-director of the Network and chairs its management and research advisory committees. Her work has expanded to research on the development of cartilage as well as bone.

A native of eastern Ontario, Dr. Aubin grew up under the influence of her first role model, her mother, who was a teacher. Although her parents never insisted on any particular career path, the fact that her mother worked outside the

home made it seem normal for women to have a career. As a high school student, Dr. Aubin considered becoming a French interpreter or a scientist. Two female high school teachers who taught chemistry and mathematics were the best teachers she ever had and their enthusiasm for science probably inspired Dr. Aubin to choose science over languages and to choose chemistry and mathematics over other sciences. They also demanded the best of their students.

One of her chemistry professors at Queen’s University tried to steer her towards a career in chemistry and he almost succeeded. At the end of her first year, she decided she liked science and abandoned the idea of studying languages. However, after completing a B.Sc. (Honours) Dr. Aubin decided to obtain her PhD at the University of Toronto in medical biophysics. She was shocked to discover that no female student had ever completed the program in medical biophysics and had to confront the fact that men and women were treated differently by some faculty members. Nevertheless, she describes the medical biophysics department as “a wonderful place to train people to become independent scientists. They thought every student they accepted should become a great scientist.” After completing her post-doctoral studies at the Max Planck Institute in Goettingen, Germany, she returned to the University of Toronto and was appointed Assistant Professor in Oral Biology.

Dr. Aubin began working seriously on bone almost by accident. She was interested in developmental biology which allowed her to ask fundamental questions that were not initially disease related. Studying how bone is formed led her to ask what affects it and if bone

does not form properly, why. Osteoporosis and arthritis are models by which you can ask why.

While President of the American Society of Bone and Mineral Research (ASBMR), Dr. Aubin wanted to raise the profile and recognize the value of good mentorship to career development within the bone field. She therefore initiated the idea of a mentoring award and subsequently chaired a committee that developed criteria for what is now an annual and prestigious ASBMR mentorship award. Dr. Aubin mentors her trainees both while they’re in her lab and after. In her view, “an important



Dominic Falconi, senior PhD student working on the effects of leukemia inhibitory factor on bone formation and development, and Dr. Jane Aubin

part of mentoring is to create an environment that makes you rise to the occasion. I hope I had a positive influence on everyone who came through the lab.” She also mentors other trainees and young investigators in Canada and elsewhere.

Dr. Aubin’s students value that positive influence. Vanessa Kung is a CAN-funded trainee who joined Dr. Aubin’s lab as a 4th year B.Sc. research elective student. She returned as a master’s student and is working on identifying novel target genes for estrogen receptor related receptor alpha (ERR $\alpha$ ) and how these genes mediate ERR $\alpha$  function in bone. She says, “Dr. Aubin is one of the best supervisors I ever worked with. She is very supportive and encourages us to try different experiments. She has enlightened my mind and broadened my thinking. Dr. Aubin is my role model.” ■



## Canadian Arthritis Network 2003 Annual Scientific Conference

Plan to attend the Canadian Arthritis Network's 2003 Annual Scientific Conference in Montreal, November 13-15. You will hear about the latest developments and meet the scientists who are on the leading edge of arthritis research. Register early and save up to \$250. Key dates are:

Deadline for early registration  
**July 10, 2003**

Deadline for submission of abstracts  
**September 30, 2003**

Deadline for application for travel awards  
**September 30, 2003**

Final program  
**September 30, 2003**

Visit [www.arthritisnetwork.ca](http://www.arthritisnetwork.ca) to register.

Travel awards are available to graduate students and post-doctoral fellows involved in CAN research.

Please visit the Web site for further information.

# 2003 Annual Scientific Conference Program

THURSDAY, NOVEMBER 13, 2003

- 4:00 p.m. **Registration**
- 5:00 p.m. **Poster exhibit and welcoming reception**
- 6:30 p.m. **Industry forum**  
Pharmaceutical industry overview: a focus on arthritis  
IMS Health, Gary Fabian  
Profiling CAN's partnership successes and opportunities  
Aventis, Dr. Karl Rudolphi  
Isotechnica, Dr. Robert Foster
- 8:00 p.m. **Light dinner**

FRIDAY, NOVEMBER 14, 2003

- 7:00 a.m. **Registration and continental breakfast**
- 8:00 a.m. **Update on CAN**  
Dr. Robin Poole, scientific co-director, Canadian Arthritis Network  
Dr. Jane Aubin, scientific co-director, Canadian Arthritis Network
- 8:30 a.m. **Feature I**  
Dr. Linda Sandell, Washington University School of Medicine  
*Cell biology of arthritis: the chondrocyte's response to injury*
- 9:15 a.m. **CAN research showcase I**  
Dr. Frank Jirik, University of Calgary  
*The mouse that roared: transgenic avenues in arthritis research*  
Dr. Ann Clarke, McGill University Health Centre  
*Malignancy and lupus*  
Dr. Greg Downey, University of Toronto  
*Regulation of inflammatory signalling by perturbation of adhesion complexes*
- 10:45 a.m. **Break**
- 11:15 a.m. **Feature II**  
Dr. Matt Liang, Harvard Medical School  
*Investigator-initiated clinical trials: too little, too late and imperilled*
- 12:00 p.m. **Canadian Rheumatology Research Consortium**  
Dr. Boulos Haraoui, Hôpital Notre-Dame du Centre hospitalier de l'Université de Montréal  
*CRRC – leading arthritis clinical research in Canada*
- 12:30 p.m. **Lunch**  
Peter Calamai, national science reporter, the Toronto Star  
*The perils, pitfalls and pleasures of science reporting*
- 2:00 p.m. **CAN research showcase II**  
Dr. Paul Fortin, University of Toronto  
*Disease progression in osteoarthritis: are all patients on the same downhill slope*  
Dr. Bill Cole, Hospital for Sick Children  
*Molecular pathology of osteoarthritis in young individuals*  
Dr. Hani El Gabalawy, University of Manitoba  
*The effects of therapy on RA synovitis: an integrated approach*  
Dr. John Matyas, University of Calgary  
*Pre-clinical biomarkers for osteoarthritis onset and progression*
- 4:00 p.m. **Break**

- 4:30 p.m. **Workshop I**  
**Media relations training**  
Facilitator: Rhea Cohen, Canadian Arthritis Network
- 5:15 p.m. **Workshop II**  
**How to write a CAN research proposal**  
Facilitator: Dr. Tineke Meijers, Canadian Arthritis Network
- 6:00 p.m. **Poster exhibit / Wine and cheese**
- SATURDAY, NOVEMBER 15, 2003
- 7:30 a.m. **Registration and breakfast**
- 8:00 a.m. **Workshop III**  
**Commercialization of intellectual property**  
Facilitator: Dr. Tineke Meijers, Canadian Arthritis Network
- 9:00 a.m. **Feature III**  
Dr. Ed Keystone, University of Toronto  
*Emerging therapies in rheumatoid arthritis*
- 9:45 a.m. **CAN research showcase III**  
Dr. Fawzi Aoudjit, Centre de recherche du Centre hospitalier de l'Université Laval  
*Regulation of T cell apoptosis by integrin signalling*  
Dr. Jim Johnson, St. Joseph's Health Centre  
*Computer-assisted knee surgery*  
Dr. Gillian Hawker, Women's College Campus of Sunnybrook and Women's College Hospital  
*Disparity in access to hip and knee arthroplasty*
- 9:45 a.m. **Workshop IV**  
**Career development for trainees**  
Facilitator: Dr. Jeff Dixon, University of Western Ontario
- 11:15 a.m. **Break**
- 11:45 a.m. **Feature IV**  
Dr. Chris Evans, Harvard Medical School  
*Gene therapy in rheumatoid arthritis*
- 12:30 p.m. **CAN Consumer Advisory Council**
- 1:00 p.m. **Lunch**
- 2:00 p.m. **Abstract presentations**  
CAN trainees
- 3:00 p.m. **Feature V**  
Dr. Harri Reddi, University of California – Davis  
*Regeneration of articular cartilage: signals, stem cells and scaffolds*
- 3:45 p.m. **Break**
- 4:15 p.m. **CAN research showcase IV**  
Dr. Michael Underhill, University of Western Ontario  
*Molecular mechanisms regulating cartilage formation*  
Dr. Maria Fernandes, Centre de recherche du Centre hospitalier de l'Université Laval  
*Angiotenin-like proteins and rheumatoid arthritis*  
Dr. David Hart, University of Calgary  
*Mechanobiology: from gene expression to tissue function*
- 5:45 p.m. **Closing remarks**
- 7:00 p.m. **Banquet dinner**  
Guest speaker: Dr. Jim Witter, U.S. Food and Drug Administration  
*How new technologies may impact on drug development in arthritis*

## Workshops

The workshops offer practical advice and “how to” information that you will not want to miss. Participants must register to attend.

### Workshop I

Media relations training  
Friday, November 14, 2003  
4:30 p.m.

You can feel confident in a media interview and look good on the six o'clock news. The media relations training workshop will teach you how to prepare for an interview, develop a “sound bite” and deliver your message.

### Workshop II

How to write a CAN research proposal  
Friday, November 14, 2003  
5:15 p.m.

CAN is different from granting agencies and research proposals must reflect CAN's objectives. Learn how to maximize your chances for funding success.

### Workshop III

Commercialization of intellectual property  
Saturday, November 15, 2003  
8:00 a.m.

CAN facilitates the development and commercialization of intellectual property. This workshop will teach you how best to protect your work and maximize the investments and the exposure.

### Workshop IV

Career development for trainees  
Saturday, November 15, 2003  
9:45 a.m.

CAN is committed to attracting, retaining and developing highly qualified trainees. This workshop is specifically designed for trainees and will talk about different career paths and the challenges and opportunities. ■

## The next generation

continued from page 2

she has learned that being a researcher is not just about doing research, but also in learning how to communicate your findings. She finds the environment very nurturing. In turn, she has developed

**“if you are interested in doing research, don’t be shy about approaching people at the university. Find someone who is willing to share their enthusiasm for research.”** | Dr. David Hart

mentoring relationships with the undergraduate summer students who have been in Dr. Hart’s laboratory, some of whom are returning this summer to work in the lab.

Under the leadership of Dr. Ron Zernicke, Dr. Hart and colleagues instituted the Markin-Flanagan Undergraduate

Research Program in Bone and Joint Health to raise the profile of such research for undergraduates so they will realize there are opportunities for them. His advice to students is “if you are interested in doing research, don’t be shy about approaching people at the university. Find someone who is willing to share their enthusiasm for research.”

The program and the available supervisors are listed on the University of Calgary Web site [www.ucalgary.ca](http://www.ucalgary.ca), and this summer there are more than 20 students in four faculties at the University of Calgary supported by the program. The students meet over the summer and share their research experiences. These students, plus others supported by agencies such as NSERC and in Alberta, the Alberta Heritage Foundation for Medical Research Summer Student Program, are the future arthritis and musculoskeletal health researchers and Dr. Hart believes that mentoring them early in their careers will help them become more effective investigators in the collaborative biomedical research environment of the future, such as that exemplified by the Canadian Arthritis Network. ■

# Canadian Arthritis Network Annual General Meeting

Please join us at our Annual General Meeting on Tuesday, August 26, 2003 at 5:30 p.m.

A reception will be held after the meeting.

The annual general meeting is an opportunity for you to meet Canada’s leading arthritis researchers, Network management and staff. Please join us and learn more about the Network’s scientific accomplishments, people and services.

Metropolitan Hotel  
Toronto Ballroom, 2nd floor  
108 Chestnut Street  
Toronto, Ontario

RSVP  
Canadian Arthritis Network  
Telephone 416-586-4798  
E-mail [can@arthritisnetwork.ca](mailto:can@arthritisnetwork.ca)



CANADIAN ARTHRITIS NETWORK | LE RÉSEAU CANADIEN DE L'ARTHRITE

Chris Nelson  
President and CEO

#### Management Committee

Jane Aubin, PhD  
Chair  
Scientific Co-Director

Linda Bennett  
Director, Clinical Research Services

Rhea Cohen  
Director, Public and Corporate Affairs

Jeff Dixon, DDS, PhD  
CAN Member

David Hart, PhD  
CAN Member

Cheryl Koehn  
Co-Chair, Consumer Advisory Council

George McKiel, PhD  
Co-Chair, Consumer Advisory Council

Tineke Meijers, PhD  
Executive Director, Research and Development

Chris Nelson  
President and CEO

Robin Poole, PhD, D.Sc.  
Scientific Co-Director

Johnathan Riley, MHA  
Director of Information, Research and Analysis

#### Canadian Arthritis Network

250 Dundas Street West  
Suite 402

Toronto ON M5T 2Z5

Tel: 416-586-4770

Fax: 416-586-8395

E-mail: [can@arthritisnetwork.ca](mailto:can@arthritisnetwork.ca)

[www.arthritisnetwork.ca](http://www.arthritisnetwork.ca)

#### JointVentures

Published by the  
Canadian Arthritis Network

Editor: Rhea Cohen

416-586-4861

Design: Stokely Design Associates Inc.



Member of the Networks of  
Centres of Excellence